Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 3/20 | 0.59 |
| ▸ | MAOB | P27338 | 2/20 | 0.56 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.53 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13312278 | 0.90 | MAOB (0.60) | MAOBMRGPRX4SMN1; SMN2MAPTCYP2C9 | |
| SCHEMBL131229 | 0.89 | FOLH1 (0.63) | MAOBMRGPRX4SMN1; SMN2MAPTCYP2C9 | |
| SCHEMBL551533 | 0.86 | PARP1 (0.57) | PARP1PARP10SMN1; SMN2MAPTCYP2C9 | |
| SCHEMBL17747123 | 0.85 | MAOB (0.55) | MAOBMRGPRX4SMN1; SMN2MAPTCYP2C9 | |
| SCHEMBL131382 | 0.85 | MAOB (0.55) | MAOBMRGPRX4SMN1; SMN2MAPTCYP2C9 | |
| SCHEMBL3123036 | 0.84 | MAOB (0.64) | MAOBMRGPRX4SMN1; SMN2MAPTCYP2C9 | |
| SCHEMBL6895376 | 0.84 | PARP1 (0.57) | PARP1PARP10SMN1; SMN2L3MBTL1SMPD1 | |
| SCHEMBL9236564 | 0.83 | SMPD1 (0.73) | MAOBMRGPRX4SMN1; SMN2SMPD1HDAC1 | |
| SCHEMBL2009073 | 0.83 | CREBBP (0.66) | MAOBMRGPRX4PARP10SMN1; SMN2MAPT | |
| SCHEMBL966146 | 0.83 | MAOB (0.52) | MAOBMRGPRX4SMN1; SMN2MAPTCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2670734-A1 | NOVEL ETHER LINKED COMPOUNDS AND IMPROVED TREATMENTS FOR CARDIAC AND CARDIOVASCULAR DISEASE | UNIVERSITY OF NOTTINGHAM (GB) | 2013-12-11 | — | — | EP | disclosed |
| US-20130261178-A1 | PHENOXYPROPANOL DERIVATIVES AND THEIR USE IN TREATING CARDIAC AND CARDIOVASCULAR DISEASES | MISTRY SHAILESH (GB) | 2013-10-03 | — | — | US | disclosed |
| EP-2590937-A1 | PHENOXYPROPANOL DERIVATIVES AND THEIR USE IN TREATING CARDIAC AND CARDIOVASCULAR DISEASES | The University Of Nottingham (GB) | 2013-05-15 | — | — | EP | disclosed |
| WO-2012104659-A1 | NOVEL ETHER LINKED COMPOUNDS AND IMPROVED TREATMENTS FOR CARDIAC AND CARDIOVASCULAR DISEASE | UNIVERSITY OF NOTTINGHAM (GB) | 2012-08-09 | — | — | WO | disclosed |
| WO-2012004549-A1 | PHENOXYPROPANOL DERIVATIVES AND THEIR USE IN TREATING CARDIAC AND CARDIOVASCULAR DISEASES | THE UNIVERSITY OF NOTTINGHAM (GB) | 2012-01-12 | — | — | WO | disclosed |
| US-7022716-B2 | Cyclic amine phenyl beta-3 adrenergic receptor agonists | WYETH (US) | 2006-04-04 | — | — | US | disclosed |
| US-6605618-B2 | Antidiabetic agents; hypoglycemic agents; anticholesterol agents; side effect reduction | WYETH | 2003-08-12 | — | — | US | disclosed |
| US-20030144326-A1 | Cyclic amine phenyl beta-3 adrenergic receptor agonists | WYETH | 2003-07-31 | — | — | US | disclosed |
| EP-1301482-A1 | CYCLIC AMINE PHENYL BETA-3 ADRENERGIC RECEPTOR AGONISTS | Wyeth (US) | 2003-04-16 | — | — | EP | disclosed |
| US-6525202-B2 | E.g., substituted (4-amino-5-hydroxyphenyl)-oxy-)piperidinyl thiazolidin-2,4-dione; antidiabetic agents; atherosclerosis, gastrointestinal, metabolic disorders, glaucoma, neurogenetic inflammation, ocular hypertension and frequent urination | WYETH | 2003-02-25 | — | — | US | disclosed |
| US-20030018045-A1 | Heterocyclic beta-3 adrenergic receptor agonists | WYETH (US) | 2003-01-23 | — | — | US | disclosed |
| US-6451814-B1 | SUBSTITUTED 4-((4-AMINO-5-HYDROXYPHENYL)-OXY-)PIPERIDINE ANALOGS; METABOLIC DISORDERS; ANTIDIABETIC AGENTS; ATHERO-SCLEROSIS, GASTROINTESTINAL DISORDERS, GLAUCOMA, NEUROGENETIC INFLAMMATION, OCULAR HYPERTENSION AND FREQUENT URINATION | WYETH | 2002-09-17 | — | — | US | disclosed |
| US-20020028832-A1 | Heterocyclic beta-3 adrenergic receptor agonists | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-03-07 | — | — | US | disclosed |
| US-20020028835-A1 | Cyclic amine phenyl beta-3 adrenergic receptor agonists | WYETH | 2002-03-07 | — | — | US | disclosed |
| WO-2002006232-A1 | CYCLIC AMINE PHENYL BETA-3 ADRENERGIC RECEPTOR AGONISTS | WYETH (US) | 2002-01-24 | — | — | WO | disclosed |
| WO-2002006229-A2 | HETEROCYCLIC BETA-3 ADRENERGIC RECEPTOR AGONISTS | WYETH (US) | 2002-01-24 | — | — | WO | disclosed |
| EP-0114758-B1 | +/- 2-((3,4-METHYLENEDIOXY)PHENETHYL)-5-((3-CARBOXAMIDO-4-HYDROXY)-ALPHA-HYDROXYBENZYL)PYRROLIDINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, PROCESS FOR THEIR PRODUCTION AND INTERMEDIATES THEREFOR | SYNTEX (U.S.A.) INC. (US) | 1986-11-12 | — | — | EP | disclosed |
| EP-0114758-A1 | +/- 2-((3,4-Methylenedioxy)phenethyl)-5-((3-carboxamido-4-hydroxy)-alpha-hydroxybenzyl)pyrrolidines, pharmaceutical compositions containing them, process for their production and intermediates therefor | SYNTEX (U.S.A.) INC. (US) | 1984-08-01 | — | — | EP | disclosed |
| EP-0009702-A1 | A phenylalkylaminoethylsalicylamide, its preparation and pharmaceutical compositions containing it | SCHERING CORPORATION (US) | 1980-04-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144326-A1 | Cyclic amine phenyl beta-3 adrenergic receptor agonists | ADRB1, ADRB3, ADRB2 | PARP1 1574/4885MAOB 786/4885MRGPRX4 100/4885 |
| US-20130261178-A1 | PHENOXYPROPANOL DERIVATIVES AND THEIR USE IN TREATING CARDIAC AND CARDIOVASCULAR DISEASES | NR3C2, NPR3, ADRB3 | PARP1 3322/4885MAOB 1022/4885MRGPRX4 736/4885 |
| US-20030018045-A1 | Heterocyclic beta-3 adrenergic receptor agonists | ADRB2, ADRB1, ADRB3 | PARP1 2993/4885MAOB 518/4885MRGPRX4 81/4885 |
| US-20020028832-A1 | Heterocyclic beta-3 adrenergic receptor agonists | ADRB1, ADRB3, ADRB2 | PARP1 2897/4885MAOB 646/4885MRGPRX4 115/4885 |
| US-20020028835-A1 | Cyclic amine phenyl beta-3 adrenergic receptor agonists | ADRB1, ADRB3, ADRB2 | PARP1 1574/4885MAOB 786/4885MRGPRX4 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.